Abstract Edotecarin (PHA-782615; formerly J-107088) is a derivative of NB-506, an
indolocarbazole antitumor agent. It is a novel inhibitor of topoisomerase I that induces single …

The goal of treatment for patients with advanced cancer is to prolong survival, control
symptoms, and reduce disease-related complications. Despite the introduction of many …

Abstract Purpose: Edotecarin (J-107088) is a potent indolocarbazole topoisomerase I
inhibitor which is structurally distinct from the camptothecins. This study aimed to determine …

Topoisomerase-1 is a key sub-cellular target for anti-cancer therapy. This intranuclear
enzyme, responsible for DNA replication and repair, undergoes interaction with …

Physicians and patients alike have been heartened by the recent advances in the treatment
of colorectal cancer. The emergence of novel agents that are active in the treatment of this …

Colorectal cancer is a common disease with a high rate of mortality and very well-
understood genetics. Primary therapy still consists of relatively non-specific treatments …

Alkylating agents and topoisomerase II inhibitors are the most common classes of
chemotherapy associated with the development of treatment-related myelodysplastic …